Author:
Iede Kiyotsugu,Yamada Terumasa,Koh Masahiro,Ueda Masami,Tsuda Yujiro,Nakashima Shinsuke,Ohta Katsuya,Tanida Tsukasa,Matsuyama Jin,Ikenaga Masakazu,Tominaga Shusei
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Endocrinology,Hepatology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference8 articles.
1. Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer;Cancer Rep (Hoboken),2020
2. Predictive implications of decreased CA19-9 at 8 weeks during nab-paclitaxel plus gemcitabine for the induction of second-line chemotherapy for patients with advanced pancreatic cancer;Cancer Rep (Hoboken),2020
3. Multiple liver metastases rather than the presence of liver metastasis is a significantly poor prognostic factor for patients with advanced pancreatic cancer;Pancreas,2020
4. Center for Cancer Control and Information Services, National Cancer Center,2020
5. A multicenter retrospective study of gemcitabine plus nab-paclitaxel for elderly patients with advanced pancreatic cancer;Pancreas,2020
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献